You are here: Industry Insights > REN001

News List

Reneo Receives EMA Orphan Drug Designations for Treatment of LCHAD Deficiency americanpharmaceuticalreview
September 16, 2020
Reneo Pharmaceuticals announced the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products has granted the company orphan drug designation for REN001, an investigational medicine in development for the treatment of LCHAD deficiency ...
Reneo Receives FDA Orphan Drug Designation for Primary Mitochondrial Myopathies Treatment americanpharmaceuticalreview
July 03, 2020
Reneo Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company's lead drug candidate, REN001, for the treatment of primary mitochondrial myopathies ...
FDA Grants Orphan Drug Designation to Reneo for REN001 americanpharmaceuticalreview
September 23, 2019
Reneo Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company's lead drug candidate ...